Health · Under review · 4 sources combinedp. 1 / 1
Personalized cancer vaccine phase 3
Recurrence, death risk down 42%
In short
Moderna and Merck's personalized mRNA cancer vaccine showed positive results in a phase 3 trial for melanoma.
Patients who received the vaccine together with the immunotherapy drug Keytruda had a 42% lower risk of recurrence and death.
The results leaked before the conference presentation, causing Moderna's stock to plunge 17.6% in a single day.
Key facts
| When | Moderna and Merck announced phase 3 clinical trial results on October 22 (local time). |
|---|---|
| Who | A cancer vaccine for melanoma patients jointly developed by Moderna and Merck (MSD). |
| What | Personalized mRNA vaccine 'Intismeran' combined with Keytruda lowered recurrence and death risk by 42%. |
| How | 1,137 patients who had their cancer surgically removed were monitored for 24.6 months. |
What it means for me
Treatment options for melanoma patients after surgery may expand.
